l really do not see the upside for Arrow, as they have already been marketing Sigma products and have a far superior sales team. In time Arrow would dwarf Sigma as its sales are increasing exponentially higher.
l also note around 5 mil in performance options which rather dwarfs the 2 - 3 mil in synergism savings. Seeems that directors will take quick profits and move along. Certainly see AWP with lower growth in the future. Cannot justify PE of 39 ! Looks like PE of 24 coming up
AWP
arrow pharmaceuticals limited
merger, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)